SEGO represents the second level of ovarian rejuvenation therapy, introducing stem cells as a key component to further enhance and restore ovarian function. Positioned between 

Bio IVF (Level 1) and SEGOVA and Dual SEGOVA (Level 3), it offers a more advanced regenerative approach while maintaining a minimally invasive profile.

​

Stem cells, with their ability for self-renewal, differentiation, immunomodulation, and angiogenesis, offer significant therapeutic potential in regenerative reproductive medicine. Intra-ovarian administration enhances hormone levels, follicle activation, angiogenesis, and ovarian function. They support follicle development, reduce inflammation and oxidative stress, and improve the ovarian microenvironment, leading to better egg quality and lower genetic risks.

​

Active principles in SEGO procedure:

​

1. hc PRP – Activated autologous highly concentrated platelet growth factors (hcPRP)

2. BRF – Activated autologous bio-regenerative fibrin (BRF)

3. SC - one type of stem cells

4. TPE – Therapeutic Plasma Exchange

5. Metabolic and physical optimization - Patient's participation in metabolic optimization and specific training

 

SEGO procedure consists of the following:

​

1. Preparation:

• one or more days or weeks of preparation, including analyses of hormones, immunological status, infections, metabolism, vitamins, micro-elements and genetics.  

 
2. Performing of SEGO Procedure:​​

​​

• outpatient - daily hospital, general anaesthesia

• blood is drawn from the patient to isolate and concentrate autologous PRP, BRF (fully automatized closed system) and autologous thrombin

• therapeutic plasma exchange (TPE)

• mobilization and separation/processing of the SC (apheresis - fully automatized closed system)

• cryopreservation of the SC surplus (optional)

• creation of subcortical tunnels for the SC (ultrasound guided)

• re-transplantation application of autologous activated BRF scaffold in the adequate subcortical tunnels (ultrasound guided)

• application of the SC and autologous activated hcPRP into the adequate subcortical spaces (ultrasound guided)

• closure of the tunnels with the activated autologous BRF (ultrasound guided)

• control of hemostasis

• discharge from the hospital the same day

​

3. The additional activities:

• the nutritionist for metabolic optimisation and the physiotherapist gonadal HIIT program

 
4. Reproductive follow-up:

• regular ultrasound and laboratory follow-up